Pennsylvania State Facts & Resources PBM Savings and Patient Impact in Pennsylvania Pharmacy benefit experts secure lower prescription drug costs and enable better health outcomes for patients. PBMs will save Pennsylvanians $45B across all Pennsylvania insurance markets over ten years
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
By JC Scott, President and CEO, PCMA In the past few years, some have been pushing the narrative that pharmacy benefit companies are driving independent pharmacies out of business. Their argument seems compelling, but is it true? As we do
Recent small fluctuations year-to-year in the number of independent pharmacies has not dramatically shifted the independent pharmacy market and continues to foster a stable market.
Using a gold-standard pharmacy dataset from the National Council for Prescription Drug Programs (NCPDP) and a transparent methodology, PCMA produces credible research with a clear conclusion: there are more independent pharmacies now than any time over the last decade.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
©2024 PCMA. All Rights Reserved.
